The first rule of working for Icahn: do not talk about working for Icahn
Plus, the great lengths of H2O Asset Management and a long-shot bid emerges for 7-Eleven
Activist and his company will pay $2mn to resolve probe launched after Hindenburg Research report
Happiness is an amended and up-to-date Schedule 13D
Plus, Elliott faces its own boardroom challenge and a new twist in a UK infrastructure disaster
CVR Energy has paid out $3.2bn in dividends to feared activist’s public investment vehicle
Plus, the complex case awaiting Evergrande’s liquidators and a deal in Japan spooks investors
Securities and Exchange Commission faults ride-hailing app for failing to disclose role of director in deal
Carl Icahn is under pressure from short sellers, and his own bets
Move follows short seller Hindenburg Research saying large payouts are unsustainable
Billionaire investor pledges more collateral in deal with five lenders
Chief’s resignation follows chair’s departure from gene sequencing group
The veteran investor has seen bets against a fast-rising market turn sour
Vote to remove John Thompson is the culmination of one of the largest shareholder activism campaigns in years
Gene sequencing company heads for pivotal vote in battle with activist investor Carl Icahn
Plus, Credit Suisse bondholders get access to AT1 wipeout decree and Geely boosts stake in Aston Martin
‘If I kept the parameters I always believed in . . . I would have been fine,’ concedes activist
Jefferies! Hindenburg! Blitzkrieg! Schadenfreude!
Proxy adviser says the two executives failed to take responsibility for destructive deal for Grail
Shares plummet on news US attorney’s office sought information a day after report from short seller Hindenburg Research
Activist investor strongly denies Hindenburg allegations but he may have a more immediate problem
Legendary activist investor’s vehicle said to be overvalued in critical report
Oh, the humanity . . .
Founding directors say political wrangling causing delays to potentially life-saving blood test
Francis deSouza was awarded $26.7mn in total pay last year despite drop in genome sequencer’s market value
